3-氨基-3-苯基丙酸甲酯 | 14898-52-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基-3-苯基丙酸甲酯
• 英文名称: methyl 3-amino-3-phenylpropanoate
• 英文别名: methyl 3-amino-3-phenylpropionate；3-amino-3-phenylpropionic acid methyl ester
• CAS: 14898-52-3
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD01037010
• 分子量: 179.219
• InChiKey: XKIOBYHZFPTKCZ-UHFFFAOYSA-N

物化性质

• 熔点：
  148-149 °C
• 沸点：
  283.0±28.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基-3-苯基丙酸甲酯 在 水 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 四氯化碳 、 丙酮 为溶剂， 生成 3-苯甲酰氨基-3-苯基丙酸
  参考文献：
  名称：

  Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

  摘要：

  An extensive structure-activity relationship (SAR) study of 72 dipeptidyl boronic acid proteasome inhibitors constructed from beta-amino acids is reported. SAR analysis revealed that bicyclic groups at the RI position, 3-F substituents at the R-2 position, and bulky aliphatic groups at the R-3 position were favorable to the activities. Enzymatic screening results showed that compound 78, comprising all of these features, was the most active inhibitor against the 20S human proteasome at less than a 2 nM level, as active as the marketed drug bortezomib. Cellular assays confirmed that compound 78 was the most potent against two hematologic and some solid tumor cells with IC50 values less than 1 mu M. Pharmacokinetic profiles suggested that 78 showed higher plasma exposure and a longer half-life than bortezomib.

  DOI：

  10.1021/jm1009742
• 作为产物：
  描述：

  methyl 3-((methoxysulfonyl)amino)-3-phenylpropanoate 在 盐酸 作用下， 生成 3-氨基-3-苯基丙酸甲酯
  参考文献：
  名称：

  DE955509

  摘要：

  公开号：

文献信息

• A Versatile Catalyst for Reductive Amination by Transfer Hydrogenation
  作者：Chao Wang、Alan Pettman、John Basca、Jianliang Xiao

  DOI：10.1002/anie.201002944

  日期：——

  An iridium catalyst enables the reductive amination of carbonyl groups with unprecedented substrate scope, selectivity, and activity using formic acid as the hydrogen source (see scheme). The catalyst system provides significant improvement over commonly used boron hydrides.

  铱催化剂使用甲酸作为氢源，可实现羰基的还原胺化，具有前所未有的底物范围，选择性和活性。与常用的氢化硼相比，该催化剂体系有明显的改进。
• Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer
  作者：Yongzhi Guo、Yuqian Zhao、Guan Wang、Yi Chen、Yingnan Jiang、Liang Ouyang、Bo Liu

  DOI：10.1016/j.ejmech.2017.11.065

  日期：2018.1

  many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K

  真核延伸因子2激酶（eEF2K）是一种Ca2 + /钙调蛋白依赖性蛋白激酶，属于非典型Ser / Thr蛋白激酶的小家族。最近有报道称eEF2K在许多类型的癌症中被高度激活或过表达。因此，eEF2K被认为是有希望的治疗靶标。在这项研究中，我们通过虚拟高通量筛选发现了β-苯丙氨酸支架，并设计和合成了46种衍生物，评估了其对eEF2K的抑制活性和细胞毒性。经过几轮激酶和抗增殖活性筛选后，我们发现了具有最佳eEF2K酶促活性（IC50为5.5μM）和抗增殖活性（MDA-MB-231细胞，IC50为12.6μM，MDA）的eEF2K抑制剂（21l） -MB-436细胞，IC50为19.8μM。而且，我们发现21l可以通过MDA-MB-231和MDA-MB-436细胞的凋亡途径诱导细胞死亡。随后，我们评估了其在体内的抗肿瘤活性和诱导细胞凋亡的机制。这些结果表明21l通过在乳腺癌的异种移植小鼠模型（M
• Carbon Dioxide-Mediated C(<i>sp</i>²)–H Arylation of Primary and Secondary Benzylamines
  作者：Mohit Kapoor、Pratibha Chand-Thakuri、Michael C. Young

  DOI：10.1021/jacs.9b03375

  日期：2019.5.15

  the pharmacological importance of ortho-arylbenzylamines, however, effective ortho-C-C bond formation of free primary and secondary benzylamines using PdII remains an outstanding challenge. Presented herein is a new strategy for constructing ortho-arylated primary and secondary benzylamines mediated by carbon dioxide (CO2). The use of CO2 with Pd is critical to allowing this transformation to proceed

  通过过渡金属催化的 CH 活化形成 CC 键已成为快速制造新键的重要策略。然而，尽管邻芳基苄胺具有药理学重要性，但使用 PdII 形成游离伯胺和仲苄胺的有效邻 CC 键仍然是一个突出的挑战。本文提出了一种用于构建由二氧化碳 (CO2) 介导的邻位芳基化伯和仲苄胺的新策略。 与 Pd 的使用对于允许这种转化在相对温和的条件下进行至关重要，机械研究表明它 ( ) 直接参与速率决定步骤。此外，较温和的温度提供了无需脱保护即可直接使用或加工的游离胺产品。
• Dutch Resolution: Separationof Enantiomers with Families of Resolving Agents. A Status Report
  作者：Richard M. Kellogg、José W. Nieuwenhuijzen、K. Pouwer、Ton R. Vries、Quirinus B. Broxterman、Reinier F.P. Grimbergen、Bernard Kaptein、René M. Crois、Ellen de Wever、Karen Zwaagstra、Alexander C. van der Laan

  DOI：10.1055/s-2003-40508

  日期：——

  Dutch Resolution is the term given to the use of mixtures (families) of resolving agents in classical resolutions. In this status report an overview is given of the latest results and new (possible) families of resolving agents are introduced. The concept of families is discussed as well as the factors that come into play on use of families. Practical aspects of Dutch Resolution in particular and resolutions in general are discussed.

  荷兰决议（Dutch Resolution）是指在传统解析过程中使用混合物（族）的解析剂。在这份状态报告中，概述了最新的结果并介绍了新（可能）的解析剂族。讨论了族的概念以及在使用族时起作用的因素。特别讨论了荷兰决议的实际方面，以及一般的解析过程。
• Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
  作者：Yanqing Liu、Enkun Zhou、Kunqian Yu、Jin Zhu、Yu Zhang、Xin Xie、Jian Li、Hualiang Jiang

  DOI：10.3390/molecules13102426

  日期：——

  CCR5, as the major co-receptor for HIV-1 entry, is an attractive novel target for the pharmaceutical industry in the HIV-1 therapeutic area. In this study, based on the structures of maraviroc and 1,4-bis(4-(7-chloroquinolin-4-yl)piperazin-1-yl)butane-1,4-dione (1), which was identified using structure-based virtual screening in conjunction with a calcium mobilization assay, a series of novel small molecule CCR5 antagonists have been designed and synthesized through fragment assembly. Preliminary SARs were obtained, which are in good agreement with the molecular binding model and should prove helpful for future antagonist design. The novel scaffold presented here might also be useful in the development of maraviroc-derived second generation CCR5 antagonists.

  CCR5作为HIV-1入侵的主要共受体，是制药工业在HIV-1治疗领域的一个具有吸引力的新型靶点。本研究基于马拉韦罗克和1，4-双(4-(7-氯喹啉-4-基)哌嗪-1-基)丁烷-1，4-二酮(1)的结构，通过片段组装设计并合成了一系列新型小分子CCR5拮抗剂，其中1是通过结构虚拟筛选结合钙动员测定鉴定的。初步的SARs(构效关系)得以获得，这些SARs与分子结合模型吻合良好，有望对未来拮抗剂设计具有指导意义。本文所展示的新型骨架在开发由马拉韦罗克衍生的第二代CCR5拮抗剂中可能还有用武之地。